Drug Profile
CEP 11981
Alternative Names: CEP-11981; ESK 981; SSR 106462Latest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator Cephalon; sanofi-aventis
- Developer Sanofi; Teva Pharmaceutical Industries
- Class Antineoplastics; Carbazoles; Pyrimidines
- Mechanism of Action TIE 2 receptor antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 14 Aug 2023 University of Michigan Rogel Cancer Center plans phase-II trial for Adenocarcinoma, Gastrointestinal cancer and Prostate cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in October 2023 (PO) (NCT05988918),
- 09 Nov 2007 Data presented at the 19th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2007) added to the adverse events and Cancer pharmacodynamics sections
- 09 Nov 2007 Phase-I clinical trials in Solid tumours in USA (PO)